▟ Vinebot intrinsic value, daily

← back

DGX Quest Diagnostics

healthcare · valued with opus medium conviction · deep-dived 2026-10-20

HOLD
Intrinsic value$134.62
Price (at call)$234.91
Margin of safety -42.7%
vs market (rating basis) +1.4%

A steady lab duopolist that compounds slowly; fairly priced unless reimbursement cuts bite hard.

The story

Quest Diagnostics is one half of the US clinical lab duopoly with LabCorp. Its moat comes from scale and density in routine testing, its patient service center network, payer contracts and hospital outreach relationships, which together give it low unit costs. It is a mature, cash-generative business that grows mid-single digits, organically from test volume and advanced diagnostics and through tuck-in acquisitions of hospital outreach labs. Its biggest overhang is reimbursement pressure from PAMA and commercial payers.

Growth of about 5.5% reflects TTM momentum from organic volume plus recent outreach acquisitions, fading to 3.5%, which is near nominal GDP and below the risk-free rate. The margin target of 16.5% is in line with the adjusted (ex-amortization) margins Quest has historically earned, helped by automation and Invigorate cost savings, not a peak. Incremental sales-to-capital of 1.5 sits above the goodwill-heavy historical 0.89 because organic growth needs little capital, though acquisitions remain expensive. The baseline DCF's -53% gap suggests its drivers were too punitive for a stable, heavily covered duopolist.

Value drivers

Revenue growth (Y1)5.5%
Terminal growth3.5%
Forecast horizon8y
Target operating margin16.5%
Years to target margin5
Sales-to-capital1.50
Beta0.85
Failure probability1.0%
Cost of capital (WACC)8.4%
Terminal WACC8.9%

Valuation bridge

PV of explicit FCFF7.39B
PV of terminal value13.27B
Equity value14.86B
÷ shares → per share$134.62

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 12.20B 5.5% 14.9% 1.38B 423.87M 958.33M 884.22M
2 12.83B 5.2% 15.3% 1.49B 423.95M 1.07B 910.87M
3 13.46B 4.9% 15.7% 1.61B 421.61M 1.19B 932.77M
4 14.09B 4.6% 16.1% 1.73B 416.75M 1.31B 949.85M
5 14.70B 4.4% 16.5% 1.85B 409.26M 1.44B 962.11M
6 15.30B 4.1% 16.5% 1.92B 399.09M 1.52B 940.40M
7 15.88B 3.8% 16.5% 2.00B 386.19M 1.61B 916.47M
8 16.44B 3.5% 16.5% 2.07B 370.56M 1.70B 890.50M

Key risks

  • PAMA Medicare clinical lab fee cuts resuming, along with commercial payer rate pressure
  • Overpaying for hospital outreach acquisitions, which erodes returns on capital
  • Volume share loss to hospital systems, at-home and point-of-care testing, or Amazon/retail health entrants

Catalysts

  • Legislative delay or reform of PAMA cuts (SALSA Act)
  • Margin expansion from AI/automation savings and accretive integration of outreach deals

History

DatePriceIntrinsicMoSRating
2026-10-20$234.91 $134.62 -42.7% HOLD
2026-08-31$242.76 $123.02 -49.3% HOLD
2026-07-09$208.21 $109.43 -47.4% HOLD
2026-06-23$197.18 $112.84 -42.8% HOLD